Sanofi
NASDAQ:SNYDrug Manufacturers - General
-$0.31 today
- Market cap
- $113.15B
- Beta
- 0.28
- P/E (TTM)
- 8.5
- EPS (TTM)
- $8.60
- Dividend yield
- 5.62%
Volume 2.32M
Average 2.78M
SNY EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
SanofiNASDAQ: SNY
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA growth accelerates
Q2 FY2026 EBITDA of €4.04B rose 23.5% year over year, ahead of the +15.5% change in trailing-twelve-month EBITDA. Sequentially, it rose 48.7% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.
Context
- EBITDA amounted to 26.7% of revenue in FY2025, up 1.8 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of €17.25B (+38.3%) for the fiscal year ending Dec 2026, a step up from the +13.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- €4.04B+48.7% QoQ
- Last fiscal yearDec 2025
- €12.48B+13.1% YoY
- LTMJun 2026
- €14.77B+15.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +23.5% | +11.0% | -12.5 pp |
| 1 year | +13.1% | +38.3% | +25.2 pp |
| 3-year CAGR | -2.6% | +13.5% | +16.1 pp |
| 5-year CAGR | +9.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
EUR · from the income statement
- Latest · FY2025
- 12.48B EUR
- Year-over-year change
- +13.1%
- 4-year CAGR
- +2.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.48B | +13.1% |
| FY2024 | 2024-12-31 | 11.03B | -3.1% |
| FY2023 | 2023-12-31 | 11.39B | -15.7% |
| FY2022 | 2022-12-31 | 13.51B | +17.1% |
| FY2021 | 2021-12-31 | 11.54B | — |
EBITDA vs competitors
How SNY compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.5% is the 3rd highest of 11, against a peer median of +3.4%.
- EBITDA amounts to 30.2% of revenue for SNY, versus a peer median of 34.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 180.91B DKK | +4.7% | +26.8% | 54.9% | |
| LTM Jun 2026 | $43.3B USD | +103.7% | +54.1% | 54.4% | |
| LTM Jun 2026 | $22.26B USD | -2.0% | +16.1% | 40.0% | |
| LTM Sep 2026 | $21.37B USD | +18.6% | +29.7% | 34.4% | |
| LTM Jun 2026 | $17.62B USD | +10.8% | +11.6% | 46.2% | |
| LTM Jun 2026 | $16.82B USD | +11.6% | -7.5% | 34.2% | |
| LTM Jun 2026 | €14.77B EUR | +15.5% | -2.6% | 30.2% | |
| LTM Jun 2026 | $13.93B USD | -44.4% | +9.9% | 21.0% | |
| LTM Jun 2026 | $13.49B USD | -33.1% | -25.8% | 21.2% | |
| LTM Jun 2026 | £8.8B GBP | +2.2% | +6.5% | 26.5% | |
| LTM Jun 2026 | $1.33B USD | -87.8% | +15.3% | 4.4% | |
| Peer median (excluding SNY) | — | +3.4% | +13.4% | 34.3% | |
Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 39.18B | 40.56B | 41.62B | 44.29B | 46.72B |
| Cost of Revenue | 12.26B | 11.88B | 12.63B | 13.21B | 13.05B |
| Gross Profit | 26.92B | 28.68B | 28.99B | 31.08B | 33.67B |
| Gross Margin | 68.7% | 70.7% | 69.7% | 70.2% | 72.1% |
| Research & Development | 5.69B | 6.5B | 6.51B | 7.39B | 7.84B |
| Selling, General & Admin | 9.56B | 8.74B | 8.93B | 9.18B | 10.24B |
| Operating Expenses | 18.79B | 18.52B | 22.03B | 23.83B | 24.07B |
| Depreciation & Amortization | 3.35B | 3.11B | 4.43B | 3.59B | 5.68B |
| EBITDA | 11.54B | 13.51B | 11.39B | 11.03B | 12.48B |
| EBITDA Margin | 29.5% | 33.3% | 27.4% | 24.9% | 26.7% |
| Operating Income | 8.13B | 10.16B | 6.96B | 7.25B | 9.6B |
| Operating Margin | 20.7% | 25.1% | 16.7% | 16.4% | 20.5% |
| Interest Income | 3.13M | 168.96M | 530.5M | 457.53M | 331M |
| Interest Expense | 377.37M | 384.8M | 512.82M | 622.58M | 626M |
| Other Income / Expenses | (289M) | (170M) | (845M) | (494M) | (3.58B) |
| Income Before Tax | 7.84B | 9.99B | 6.12B | 6.76B | 6.02B |
| Pre-Tax Margin | 20.0% | 24.6% | 14.7% | 15.3% | 12.9% |
| Income Tax Expense | 1.56B | 1.91B | 1.02B | 1.2B | 1.04B |
| Net Income | 6.22B | 8.37B | 5.4B | 5.56B | 7.81B |
| Net Margin | 15.9% | 20.6% | 13.0% | 12.6% | 16.7% |
| EPS (Basic) | 2.49 | 3.19 | 2.15 | 2.19 | 3.20 |
| EPS (Diluted) | 2.49 | 3.18 | 2.15 | 2.19 | 3.20 |
| Weighted Avg Shares | 2.51B | 2.5B | 2.5B | 2.5B | 2.44B |
| Weighted Avg Shares (Diluted) | 2.51B | 2.5B | 2.51B | 2.5B | 2.44B |
Sanofi
NASDAQ:SNY
Intrinsic Alpha fair value
Locked
Current Price
$47.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.